1 Kinetics of neutralising antibodies against Omicron variant in

2 Vietnamese healthcare workers after primary immunisation with

3 ChAdOx1-S and booster with BNT162b2

- 4 Nguyen Van Vinh Chau^{1,2} Lam Anh Nguyet³, Nguyen Thanh Dung⁴, Vo Minh Quang⁴,
- 5 Nguyen Thanh Truong⁵, Le Mau Toan⁴, Le Manh Hung⁴, Dinh Nguyen Huy Man⁴, Dao
- 6 Bach Khoa⁴, Nguyen Thanh Phong⁴, Nghiem My Ngoc⁴, Huynh Phuong Thao⁴, Dinh Thi
- 7 Bich Ty⁴, Pham Ba Thanh⁴, Nguyen Thi Han Ny³, Le Kim Thanh³, Cao Thu Thuy³,
- 8 Nguyen To Anh³, Nguyen Thi Thu Hong³, Le Nguyen Truc Nhu³, Lam Minh Yen³, Guy
- 9 Thwaites^{2,3}, Tran Tan Thanh³, and Le Van Tan^{2,3}, for OUCRU COVID-19 Research
- 10 Group*
- ¹Department of Health, Ho Chi Minh City, Vietnam
- 12 ²Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
- 13 University of Oxford, Oxford, UK
- 14 ³Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
- ⁴Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
- ⁵Tan Phu Hospital, Ho Chi Minh City, Vietnam
- 17 *Members of the groups are listed in the acknowledgments.
- 18 Correspondence: Nguyen Van Vinh Chau, chaunvv@oucru.org, and Le Van Tan,
- 19 tanlv@oucru.org
- 20 Word count: abstract: 250 word, Main text: 2401 words
- 21 Running title: Neutralization of SARS-CoV-2 Omicron variant
- 22 Keywords: COVID-19, SARS-CoV-2, Omicron, vaccine, pandemic, Vietnam

23 Abstract

24 We studied the development and persistence of neutralising antibodies against SARS-25 CoV-2 ancestral strain, and Delta and Omicron (BA.1 and BA.2) variants in Vietnamese 26 healthcare workers (HCWs) up to 15 weeks after booster vaccination. We included 47 27 HCWs with different pre-existing immune statuses (group 1 (G1): n=21, and group 2 28 (G2): n=26 without and with prior breakthrough Delta variant infection, respectively). 29 The study participants had completed primary immunisation with ChAdOx1-S and 30 booster vaccination with BNT162b2. Neutralising antibodies were measured using a 31 surrogate virus neutralisation assay. Of the 21 study participants in G1, neutralising 32 antibodies against ancestral strain, Delta variant, BA.1 and BA.2 were (almost) abolished 33 at month 8 after the second dose, but all had detectable neutralising antibodies to the 34 study viruses at week two post booster dose. Of the 26 study participants in G2, 35 neutralising antibody levels to BA.1 and BA.2 were significantly higher than those to the 36 corresponding viruses measured at week 2 post breakthrough infection and before the 37 booster dose. At week 15 post booster vaccination, neutralising antibodies to BA.1 and 38 BA.2 dropped significantly, with more profound changes observed in those without 39 breakthrough Delta variant infection. Booster vaccination enhanced neutralising activities 40 against ancestral strain and Delta variant, as compared to those induced by primary 41 vaccination. These responses were maintained at high levels for at least 15 weeks. Our 42 findings emphasise the importance of the first booster dose in producing cross-43 neutralising antibodies against Omicron variant. A second booster dose might be needed 44 to maintain long-term protection against Omicron variant.

45 **INTRODUCTION**

46 COVID-19 vaccine induced immunity wanes [1, 2], which has led to the administration 47 of booster doses worldwide. Follow-up studies assessing the impact of booster 48 vaccination on the development and persistence of the immune response to SARS-CoV-2 49 and circulating variants of concern (VOC) remain critical to informing the allocation of 50 resources, policy decisions on COVID-19 mitigation measures, and the development of 51 next-generation vaccines [3].

52 Over the last 12 months, SARS-CoV-2 Delta and Omicron VOCs have been responsible 53 for two consecutive COVID-19 waves globally. Omicron variant is genetically divided 54 into five major sublineages: BA.1-5. Earlier in 2022, BA.2 replaced BA.1 to become the 55 dominant variant worldwide, including in Vietnam [4]. As of June 13th 2022, BA.4 and 56 BA.5 were responsible for the most recent waves in South Africa and Portugal [5, 6] with 57 spread reported into Europe and the USA [7].

It is thus critical to assess levels of neutralising antibodies induced by primary course and booster vaccination against Delta and Omicron variants, especially in individuals with different pre-existing immunity; e.g. breakthrough and non-breakthrough infection. Yet, most of the reported data have been from high income countries [8-14], and few studies, especially those focusing on long term immunity, have been conducted in low- and middle-income countries.

Vietnam started the national COVID-19 vaccination programme in March 2021, and introduced the first boosters in December 2021. Herein, we focused our analysis on health care workers (HCWs) of the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City (HCMC), Vietnam. Our aim was to assess the impact of the heterologous

booster on the development and persistence of neutralising antibodies against the ancestral strain, Delta and Omicron variants (BA.1 and BA.2), in HTD staff with and without prior breakthrough infection.

71 MATERIALS AND METHODS

72 Setting and the vaccine evaluation study

The present study has been conducted at HTD in HCMC since March 2021 [15]. HTD is
a 550-bed tertiary referral hospital for patients with infectious diseases in southern
Vietnam. HTD has around 900 members of staff, and has been responsible for receiving
COVID-19 patients of all severities in Southern Vietnam since the beginning of the
pandemic.

The detailed descriptions about the study cohort have previously been reported [15]. In brief, a total of 554 individuals were enrolled at baseline, and 144 were selected for followed up from the second dose onward. Two doses of Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1-S) were given as part of the primary course, completed by the first week of May 2021. And Pfizer-BioNTech COVID-19 vaccine (BNT162b2) was given as part the booster dose, completed in the third week of December 2021.

84 Weekly SARS-CoV-2 testing

As per the national COVID-19 control strategy in Vietnam, between June 2021 and March 2022, HTD staff were tested weekly for SARS-CoV-2 using either PCR or antigen tests [16]. When available, samples were subjected to SARS-CoV-2 whole-genome sequencing to determine SARS-CoV-2 variant [17]. This allowed for the detection of breakthrough infection. We previously reported a cluster of breakthrough Delta variant

90 infection among HTD staff members in June 2021 [18]. Any staff members with91 breakthrough infection requiring hospitalisation was admitted to HTD for clinical care.

92 Plasma samples for antibody measurement

93 We selected 47 HCWs from the original vaccine evaluation study, consisting of group 1

- 94 (G1) including 21 without documented breakthrough infection from baseline until booster
- 95 vaccination, and group 2 (G2), including 26 with breakthrough Delta variant infection
- 96 [15]. More detailed descriptions about the selected participants and sampling schedules
- 97 are presented in Figure 1.

98 Sample size justification

99 The 47 HCWs were selected for analysis because they had longitudinal plasma samples 100 collected from dose 2 (G1) or breakthrough infection (G2) until month 3 after the booster 101 dose. Sampling at this scale however has been proven to be sufficient to demonstrate the 102 differences in antibody responses to Omicron variant in people receiving either 103 heterologous or homologous BNT162b2 booster vaccination [13].

104 Antibody measurements

105 For measurement of neutralizing antibodies against SARS-CoV-2 original strain (herein

106 referred as ancestral) and SARS-CoV-2 Delta and Omicron variants (BA.1 and BA.2),

- 107 we used the SARS-CoV-2 Surrogate Virus Neutralization (sVNT) assay (Genescript,
- 108 USA). sVNT is a blocking ELISA that quantifies neutralizing antibodies targeting the
- 109 receptor binding domain (RBD) of S protein [19]. The experiments were carried as per
- the manufacturers' instructions with the readouts expressed as percentage of inhibition.

111 Statistical analysis

The Wilcoxon signed-rank test or the paired T-test was used to compare the differences in neutralizing antibody levels to ancestral strain, Delta, BA.1 and BA.2 between and within groups when appropriate. The Spearman's correlation was used to assess the correlation of neutralizing antibody levels and age. All analyses were performed using GraphPad Prism 9.3.1 (GraphPad Software, La Jolla, CA, USA).

117 Ethics

118 The study received approvals from the Institutional Review Board of the Hospital for

119 Tropical Diseases in Ho Chi Minh City Vietnam and the Oxford Tropical Research

120 Ethics Committee. Written informed consent was obtained from all the study participants.

121 **RESULTS**

122 **Demographics and breakthrough infection after booster vaccination**

123 Information about the demographics and vaccination status of the selected participants 124 are presented in Table 1 and Figure 1. The window time between the second dose and the 125 booster dose was around 8 months. Of the 26 participants in G2, the window time from 126 infection to booster vaccination was around 6 months (Figure 1).

During the follow up, 9 individuals, including 5/21 (24%) participants of G1 and 4/26 (15%) participants of G2, had a SARS-CoV-2 infection episode recorded after the booster dose (Figure 1). Although detailed clinical descriptions were not available, no hospitalisation was reported, suggesting that all were either asymptomatic or mildly symptomatic. E-gene real time PCR Ct values were available in two samples of G1 (13.1 and 15.4). Of these, information about SARS-CoV-2 variant was available in one; which was assigned to BA.2. The window time (median in days) from infection to blood

sampling at month three after booster vaccination was 28 (range: 12-103) for G1 and 17

135 (range: 8-22) for G2.

136 Neutralising antibodies against BA.1 and BA.2 after primary vaccination with

137 ChAdOx1-S

- 138 Of the 21 participants in G1, at week two after the primary course, detectable neutralising
- 139 antibodies against ancestral strain and Delta variant were documented in 21 (100%) and
- 140 20 (95%), with comparable levels to ancestral strain and Delta variant (Figure 2A and
- 141 Table 2). Neutralising antibodies to BA.2 were not detected, while neutralising antibodies
- against BA.1 were detected in only 3 participants but the titers approached the detection
- 143 limit of the sVNT assay (Figure 2A and Table 2).

144 Development of neutralising antibodies after heterologous booster with BNT162b2

145 in individual with and without prior breakthrough infection

146 Of the 21 participants in G1, before the booster dose (i.e. month 8 after dose 2), none had 147 detectable neutralising antibodies against Omicron variant (BA.1 and BA.2). The 148 proportions of individuals with detectable neutralising antibodies to the ancestral strain 149 and Delta variant were 8/21 (38%) and 2/21 (10%), respectively, with neutralising titers 150 approaching the assay detection limit (Figure 2A). At week 2 after the booster dose, all 151 had neutralising antibodies against ancestral strain and VOCs (Delta, BA.1 and BA.2). 152 Notably neutralising antibody levels to ancestral strain, and Delta variant measured at 2 153 weeks after the booster dose were significantly higher than those to the respective viruses 154 measured at week 2 after dose 2 (median inhibition in % (interquartile range (IQR)): for 155 ancestral strain: 97.3 (96.9-97.5) vs. 86.2 (74.6-93.8), p<0.001, and for Delta variant: 156 98.2 (98.0-98.3) vs. 86.3 (74.4-89.8), p<0.001) (Figure 2A). Neutralising antibody levels

to BA.2 were significantly higher than those to BA.1 (median inhibition in % (IQR): 92.7

158 (89.2-95.6) vs. 84.1 (74.1-90.6), p<0.001) (Figure 2A and Table 2).

159 Of the 26 participants in G2, neutralising antibodies against ancestral strain, Delta, BA.1

and BA.2 measured at week 2 after breakthrough infection were detectable in 24 (92%),

161 23 (88%), 18 (69%) and 17 (65%), respectively (Figure 2B), with neutralising antibody

162 levels to the ancestral strain and Delta variant significantly higher than those to BA.1 and

163 BA.2 (Figure 2B and Table 2). At week 2 after booster vaccination, neutralising antibody

164 levels to BA.1 and BA.2 significantly increased as compared to those measured before

165 the booster dose and at 2 weeks post breakthrough infection, but remained significantly

166 lower than those against ancestral strain and Delta variant (Figure 2B and Table 2). At

this time point, neutralising antibody levels to BA.2 were significantly higher than those

168 to BA.1 (median inhibition in % (IQR): 95.7 (90.8-97.7) vs. 92.3 (82.8-95.7), p<0.004)

169 (Figure 2B).

170 Persistence of neutralising antibodies at week 15 after booster vaccination

171 To assess the persistence of neutralising antibodies induced by the booster dose, we first 172 focused our analysis on those without a SARS-CoV-2 infection episode documented after 173 booster vaccination. At week 15 after the booster dose, of 16 study participants in G1, 16 174 (100%) had detectable neutralising antibodies against ancestral, Delta and BA.2 variants, 175 while 11/16 (69%) had detectable neutralising antibodies against BA.1. Accordingly, 176 neutralising antibody levels to BA.1 and BA.2 was significantly lower compared to those 177 measured at week 2 post booster vaccination (median inhibition in % (IQR): for BA.1: 178 54.3 (19.1-92.1) vs. 85.7 (71.3-92.1), p=0.034, and for BA.2: 83.7 (68.3-97.6) vs. 93.2

179 (90.4-95.7), p=0.034) (Figure 3A). Neutralising antibodies against Delta variant also
180 slightly reduced, but remained at very high titers (Figure 3A).

181 Of the 22 participants without a SARS-CoV-2 infection episode documented after the

182 booster dose in G2, neutralising antibody levels to BA.1 significantly decreased (median

183 inhibition in % (IQR): 87.8 (70.5-93.2) vs. 92.3 (82.5-95.8), p=0.012) (Figure 3B).

184 Otherwise, neutralising antibody levels to ancestral strain, Delta and BA.2 measured at

this time points were comparable with those of the corresponding viruses measured attwo weeks post booster dose (Figure 3B and Table 2).

187 Of the nine individuals with a documented SARS-COV-2 infection episode after the

booster dose, neutralising antibody levels to ancestral strain and all VOCs slightly

increased at week 15, albeit not statistically significant in case of ancestral strain, BA.1and BA.2 (Supplementary Figure 1).

191 Association between age and neutralising antibody levels to BA.1 and BA.2

Results of linear regression analysis showed no association between age and neutralizing antibodies levels to BA.1 and BA.2 measured at week 2 and week 15 post booster dose (Supplementary Figure 2). Similar analysis for ancestral strains and Delta variant was considered uninformative because neutralising antibody levels to these two viruses in all

196 study participants reached the upper detection limit of the assay (100%) (Figure 3).

197 **DISCUSSION**

We showed that neutralising antibodies induced by primary immunization with ChAdOx1-S in Vietnamese HCWs failed to neutralize Omicron variant BA.1 and BA.2. Heterologous booster vaccination with BNT162b2 improved the immunity that could broadly neutralize both BA.1 and BA.2 in HCWs with and without prior breakthrough

9

202 infection. Additionally, booster vaccination significantly enhanced neutralising antibody 203 levels to the ancestral strain and Delta variant. However, neutralising antibodies against 204 BA.1 and BA.2 significantly declined at month 3 post-booster vaccination, particularly in 205 those without breakthrough infection, while neutralising antibodies to ancestral strain and 206 Delta variant remained at high titers. We found no association between age and 207 neutralising antibody levels, in line with a recent report [12], but none of our study 208 participants were older than 57 years. Our findings are consistent with existing data 209 regarding the capacity of the Omicron variant to escape from neutralizing antibodies 210 induced by vaccination [10, 20]. The results also support previous findings about the 211 effectiveness of the third doses in preventing infection, severe disease and death [14].

212 Over half of the plasma samples collected at two weeks after breakthrough Delta variant 213 infection cross-neutralised BA.1 and BA.2, supporting recent reports regarding protection 214 against Omicron offered by previous infection [21-23]. Booster vaccination further 215 enhanced the cross-neutralising activities and the proportion of plasma samples with 216 detectable neutralizing antibodies in these individuals with breakthrough Delta variant 217 infection 6 months earlier [18]. Because neutralising antibodies titers are well correlated 218 with protection [24, 25], the data suggest that booster vaccination could still be beneficial 219 to individuals with breakthrough infection in protecting against Omicron variant [21, 23]. 220 Likewise, the decline in neutralsing antibody levels to sublineages BA.1 and BA.2 at 221 week 15 after the first booster dose suggest that a second booster doses might be needed 222 to maintain the long-term protection of vaccine against Omicron variant [12]. Our results 223 also compliment findings from a recent population based study in the USA [2], which 224 showed that during the Omicron wave vaccine effectiveness against hospitalizations

dropped from 91% during the first 2 months to $78\% \ge 4$ months after a third dose. Additionally, a recent study from Israel demonstrated that a second booster dose of the BNT162b2 vaccine was effective in reducing the risk of COVID-19 associated outcomes (including infection) in individuals already completing the first booster dose at least 4 months earlier [9].

230 Our study consistently showed that neutralising antibody tiers against BA.2 after the 231 booster dose in individuals with and without prior breakthrough infection were 232 significantly higher than those against BA.1. Relevant data from previous studies have so 233 far been inconsistent. Recent studies from Germany and Hong Kong showed comparable 234 serum neutralising antibody levels to BA.1 and BA.2 in individuals completing three 235 doses of BNT162b2 [8, 26]. In contrast, Yu and colleagues showed that median 236 neutralising antibody titers against BA.2 was lower than those against BA.1 in people 237 triple vaccinated with BNT162b2, and in those with previous infection regardless of the 238 vaccination status [11]. The differences in study populations and pre-existing immunity 239 induced by past exposure and/or vaccination might be contributing factors. Whether 240 BA.2 is less able to evade immunity than BA.1 merits further research.

Our study has several limitations. First, we did not perform live virus neutralisation assay, currently the gold standard, to measure neutralising antibodies. However, the percentage of inhibition measured by the sVNT test has been shown to correlate well with the neutralizing antibody titers measured by the conventional plaque reduction neutralization assay [19]. Second, we did not study T-cell responses, which have been proven to play an important role in protecting against severe disease and death, and in

case of Omicron variant, despite the neutralisation escape, T-cell responses werepreserved at around 70-80% [27, 28].

- 249 In summary, we showed that booster vaccination by BNT162b2 induced cross-
- 250 neutralising activities against sublineages BA.1 and BA.2 of Omicron variant in
- 251 Vietnamese HCWs completing primary immunization with ChAdOx1-S. These responses
- bowever significantly reduced at month 3 post booster doses, indicating a second booster
- 253 is potentially needed to maintain long-term vaccine effectiveness against the currently
- 254 circulating variants. Vaccines remains critical to reduce the transmission and to protect
- against severe disease and death.

256 ACKNOWLEDGEMENTS

- This study was funded by the Wellcome Trust of Great Britain (106680/B/14/Z, 204904/Z/16/Z and 222574/Z/21/Z).
- We thank our colleagues at the Hospital for Tropical Diseases in Ho Chi Minh City,Vietnam, for their participations in this study.

261 OUCRU Vietnam COVID-19 research group: Chambers Mary, Choisy Marc, Day 262 Jeremy, Dong Huu Khanh Trinh, Dong Thi Hoai Tam, Du Hong Duc, Dung Vu Tien 263 Viet, Fisher Jaom, Flower Barney, Geskus Ronald, Hang Vu Thi Kim, Ho Quang Chanh, 264 Ho Thi Bich Hai, Ho Van Hien, Hung Vu Bao, Huong Dang Thao, Huynh le Anh Huy, 265 Huynh Ngan Ha, Huynh Trung Trieu, Huynh Xuan Yen, Kestelyn Evelyne, Kesteman 266 Thomas, Lam Anh Nguyet, Lawson Katrina, Leigh Jones, Le Kim Thanh, Le Dinh Van 267 Khoa, Le Thanh Hoang Nhat, Le Van Tan, Lewycka Sonia Odette, Lam Minh Yen, Le 268 Nguyen Truc Nhu, Le Thi Hoang Lan, Nam Vinh Nguyen, Ngo Thi Hoa, Nguyen Bao 269 Tran, Nguyen Duc Manh, Nguyen Hoang Yen, Nguyen Le Thao My, Nguyen Minh 270 Nguyet, Nguyen To Anh, Nguyen Thanh Ha, Nguyen Than Ha Ouven, Nguyen Thanh 271 Ngoc, Nguyen Thanh Thuy Nhien, Nguyen Thi Han Ny, Nguyen Thi Hong Thuong, 272 Nguyen Thi Hong Yen, Nguyen Thi Huyen Trang, Nguyen Thi Kim Ngoc, Nguyen Thi 273 Kim Tuyen, Nguyen Thi Ngoc Diep, Nguyen Thi Phuong Dung, Nguyen Thi Tam, 274 Nguyen Thi Thu Hong, Nguyen Thu Trang, Nguyen Thuy Thuong Thuong, Nguyen 275 Xuan Truong, Nhung Doan Phuong, Ninh Thi Thanh Van, Ong Phuc Thinh, Pham Ngoc 276 Thanh, Phan Nguyen Quoc Khanh, Phung Ho Thi Kim, Phung Khanh Lam, Phung Le 277 Kim Yen, Phung Tran Huy Nhat, Rahman Motiur, Thuong Nguyen Thi Huyen, Thwaites 278 Guy, Thwaites Louise, Tran Bang Huyen, Tran Dong Thai Han, Tran Kim Van Anh, 279 Tran Minh Hien, Tran Phuong Thao, Tran Tan Thanh, Tran Thi Bich Ngoc, Tran Thi 280 Hang, Tran Tinh Hien, Trinh Son Tung, van Doorn H. Rogier, Van Nuil Jennifer,

281 Vidaillac Celine Pascale, Vu Thi Ngoc Bich, Vu Thi Ty Hang, Yacoub Sophie. HTD 282 COVID-19 research group: Nguyen Van Vinh Chau, Nguyen Thanh Dung, Le Manh 283 Hung, Huynh Thi Loan, Nguyen Thanh Truong, Nguyen Thanh Phong, Dinh Nguyen 284 Huy Man, Nguyen Van Hao, Duong Bich Thuy, Nghiem My Ngoc, Nguyen Phu Huong 285 Lan, Pham Thi Ngoc Thoa, Tran Nguyen Phuong Thao, Tran Thi Lan Phuong, Le Thi 286 Tam Uyen, Tran Thi Thanh Tam, Bui Thi Ton That, Huynh Kim Nhung, Ngo Tan Tai, 287 Tran Nguyen Hoang Tu, Vo Trong Vuong, Dinh Thi Bich Ty, Le Thi Dung, Thai Lam 288 Uyen, Nguyen Thi My Tien, Ho Thi Thu Thao, Nguyen Ngoc Thao, Huynh Ngoc Thien 289 Vuong, Huynh Trung Trieu, Pham Ngoc Phuong Thao, Phan Minh Phuong. EOCRU 290 COVID-19 research group: Bachtiar, Andy, Baird, Kevin J., Dewi, Fitri, Dien, Ragil, 291 Djaafara, Bimandra A., Elyazar, Iqbal E., Hamers, Raph L., Handayani, Winahyu, 292 Kurniawan, Livia Nathania, Limato, Ralalicia, Natasha, Cindy, Nuraeni, Nunung, 293 Puspatriani, Khairunisa, Rahadjani, Mutia, Rimainar, Atika, Saraswati, Shankar, Anuraj 294 H., Suhendra, Henry, Sutrisni, Ida Ayu, Suwarti, Tarino, Nicolas, Timoria, Diana, 295 Wulandari, Fitri. OUCRU-NP COVID-19 research group: Basnyat Buddha, Duwal 296 Manish, Gautum Amit, Karkey Abhilasha, Kharel Niharika, Pandey Aakriti, Rijal Samita, 297 Shrestha Suchita, Thapa Pratibha, Udas Summita. 298

299 **REFERENCES**

- Goldberg, Y., et al., *Waning Immunity after the BNT162b2 Vaccine in Israel.* N
 Engl J Med, 2021. **385**(24): p. e85.
- 3022.Ferdinands, J.M., et al., Waning 2-Dose and 3-Dose Effectiveness of mRNA303Vaccines Against COVID-19-Associated Emergency Department and Urgent
- 304 Care Encounters and Hospitalizations Among Adults During Periods of Delta and
- 305 Omicron Variant Predominance VISION Network, 10 States, August 2021-
- 306 *January 2022.* MMWR Morb Mortal Wkly Rep, 2022. **71**(7): p. 255-263.
- 307 3. Magen, O., et al., Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a
 308 Nationwide Setting. New England Journal of Medicine, 2022.
- 309 4. <u>https://nextstrain.org/ncov/gisaid/global/6m</u>. Accessed on 14 June 2022.
- Tegally, H., et al., Continued Emergence and Evolution of Omicron in South
 Africa: New BA.4 and BA.5 lineages. MedRxiv, 2022.
- 3126.National Institute of Health. Monitoring of COVID-19 in Portugal. 2022313Availableat:https://www.insa.min-saude.pt/wp-
- 314 content/uploads/2022/06/20220601_Monitorizacao_COVID-19.pdf.

- 315 7. Stockholm, E., European Centre for Disease Prevention and Control.
 316 Implications of the emergence and spread of the SARS-CoV-2 variants of concern
 317 BA.4 and BA.5 for the EU/EEA 14 June 2022. 2022.
- Arora, P., et al., *Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3*. The Lancet Infectious Diseases, 2022. 22(6):
 p. 766-767.
- Magen, O., et al., Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a
 Nationwide Setting. N Engl J Med, 2022. 386(17): p. 1603-1614.
- Hu, J., et al., *Increased immune escape of the new SARS-CoV-2 variant of concern Omicron*. Cellular & Molecular Immunology, 2022. 19(2): p. 293-295.
- 325 11. Yu, J., et al., *Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants*.
 326 N Engl J Med, 2022. **386**(16): p. 1579-1580.
- Lassauniere, R., et al., Neutralizing Antibodies Against the SARS-CoV-2 Omicron
 Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2
 mRNA Vaccine. JAMA Netw Open, 2022. 5(5): p. e2212073.
- 13. Cheng, S.M.S., et al., Neutralizing antibodies against the SARS-CoV-2 Omicron
 variant BA.1 following homologous and heterologous CoronaVac or BNT162b2
 vaccination. Nat Med, 2022. 28(3): p. 486-489.
- Lustig, Y., et al., Superior immunogenicity and effectiveness of the 3rd BNT162b2
 vaccine dose. MedRxiv, 2021.
- 15. Chau, N.V.V., et al., *Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers*. Am J Trop Med Hyg, 2022. **106**(2): p. 556561.
- Corman, V.M., et al., *Detection of 2019 novel coronavirus (2019-nCoV) by real- time RT-PCR*. Euro Surveill, 2020. 25(3).
- Chau, N.V.V., et al., *Rapid whole-genome sequencing to inform COVID-19 outbreak response in Vietnam.* J Infect, 2021. 82(6): p. 276-316.
- 342 18. Chau, N.V.V., et al., An observational study of breakthrough SARS-CoV-2 Delta
 343 variant infections among vaccinated healthcare workers in Vietnam.
 344 EClinicalMedicine, 2021. 41: p. 101143.

- Tan, C.W., et al., A SARS-CoV-2 surrogate virus neutralization test based on *antibody-mediated blockage of ACE2-spike protein-protein interaction*. Nat
 Biotechnol, 2020. 38(9): p. 1073-1078.
- 348 20. Dejnirattisai, W., et al., SARS-CoV-2 Omicron-B.1.1.529 leads to widespread
 349 escape from neutralizing antibody responses. Cell, 2022. 185(3): p. 467-484 e15.
- 350 21. Smid, M., et al., Protection by vaccines and previous infection against the
 351 Omicron variant of SARS-CoV-2. J Infect Dis, 2022.
- 352 22. Altarawneh, H.N., et al., *Protection against the Omicron Variant from Previous*353 SARS-CoV-2 Infection. N Engl J Med, 2022. 386(13): p. 1288-1290.
- Nyberg, T., et al., *Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.* The Lancet, 2022. **399**(10332): p. 1303-1312.
- 357 24. Gilbert, P.B., et al., *Immune correlates analysis of the mRNA-1273 COVID-19*358 vaccine efficacy clinical trial. Science, 2022. 375(6576): p. 43-50.
- 359 25. Fong, Y., et al., *Immune Correlates Analysis of a Single Ad26.COV2.S Dose in*360 *the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial.* medRxiv, 2022.
- 361 26. Chen, L.L., et al., *Serum neutralisation of the SARS-CoV-2 omicron sublineage*362 *BA.2.* Lancet Microbe, 2022. 3(6): p. e404.
- 363 27. Gao, Y., et al., Ancestral SARS-CoV-2-specific T cells cross-recognize the
 364 Omicron variant. Nat Med, 2022. 28(3): p. 472-476.
- 365 28. Tarke, A., et al., SARS-CoV-2 vaccination induces immunological T cell memory
 366 able to cross-recognize variants from Alpha to Omicron. Cell, 2022. 185(5): p.
 367 847-859 e11.

368

369 LEGENDS TO FIGURES

Figure 1: Illustration showing the distribution of the study participants and samplingschedules for neutralising antibody measurement

Figure 2: Neutralizing antibodies against SARS-CoV-2 ancestral strain and VOCs
(Delta, BA.1 and BA.2) in individuals without (A) and with (B) documented prior
breakthrough Delta variant infection measured at different time points prior to booster
vaccination and at week 2 post booster dose. Horizontal dot lines indicate assay cut-off.
Numbers indicates p values.

Figure 3: Persistence of neutralising antibodies at month 3 after the booster dose in those

378 without documented breakthrough infection after the booster dose, A) participants of G1,

and **B**) participants of G2. Horizontal dot lines indicate assay cut-off, Numbers indicates

380 p values.

| Variables | G1: HCWs without documented | G2: HCWs with breakthrough | |
|--|---------------------------------|----------------------------|--|
| | breakthrough infection prior to | infection prior to booster | |
| | booster vaccination (n=21) | vaccination, (n=26) | |
| Male gender, n (%) | 1 (4.8) | 10 (38.5) | |
| Age year, median (range) | 35 (24-54) | 40.5 (24-56) | |
| Vaccine dose 1 date (range) | 8-12 Mar/2021 | 8-15 Mar/2021 | |
| Vaccine dose 2 date (range) | 19-28 Apr/2021 | 22 Apr - 4 May/2021 | |
| Vaccine dose 3 date (range) | 16-17 Dec/2021 | 16-21 Dec/2021 | |
| Days from vaccine dose 1 to dose 2, median | 43 (40-49) | 44 (39-53) | |
| (range) | | | |
| Days from vaccine dose 2 to dose 3, median | 238 (233-241) | 238 (231-245) | |
| (range) | | | |
| Days from vaccine dose 3 to breakthrough | NA | 187 (184-191) | |
| infection, median (range) | | | |
| Breakthrough infection after booster dose, n (%) | 5 (23.8) | 4 (15.4) | |
| Days from booster vaccination to infection, | 82 (1-94) | 86 (77-96) | |
| median (range) | | | |
| Days from infection after booster dose to blood | 28 (12-103) | 17 (8-22) | |
| sampling, median (range) | | | |

Table 1: Demographics and time intervals between vaccine doses

Note to Table 1: NA: Non-applicable

Table 2: Neutralising antibody levels to ancestral strain, Delta variant, BA.1and BA.2 measured at four time points during the study period

| | | An apartual atuain | Dalta variant | DA 1 | DA 2 |
|------------------------|------------------------|--------------------|------------------|------------------|------------------|
| | | Ancestral strain | Dena variant | DA.1 | DA.2 |
| G1: HCWs without prior | 2 weeks after dose 2 | 86.2 (74.6-93.8) | 86.3 (74.4-89.8) | -4.7 (-12-9.5) | 6.1 2.9-14.4) |
| breakthrough infection | Before dose 3 | 26.9 (19.1-36.2) | 7.5 (-5.3-17.5) | -3.2 (-5.5-1) | 0 (0-3.3) |
| | 2 weeks after dose 3 | 97.3 (96.9-97.5) | 98.2 (98.0-98.3) | 84.1 (74.1-90.6) | 92.7 (89.2-95.6) |
| | 15 weeks after dose 3 | 97.5 (97.4-97.6) | 97.9 (97.4-98.1) | 54.3 (19.1-92.1) | 83.7 (68.3-97.6) |
| G2: HCWs with prior | 2 weeks after | 96.9 (81.6-97.0) | 97.6 (77.2-98.2) | 70.0 (10.9-80.8) | 85.7 (-5.2-92.4) |
| breakthrough infection | breakthrough infection | | | | |
| | Before dose 3 | 96.0 (87.8-96.6) | 97.5 (71.9-98) | 18.8 (6-46.7) | 74.1 (34.5-82.9) |
| | 2 weeks after dose 3 | 96.1 (95.8-97.5) | 98.1 (98.0-98.4) | 92.3 (82.8-95.7) | 95.7 (90.8-97.7) |
| | 15 weeks after dose 3 | 96.8 (96.7-97.0) | 98 (98.0-98.2) | 87.8 (70.5-93.2) | 94.9 (89.0-98.2) |

Note to Table 2: Reported values are median inhibition in % (interquartile range)



Figure 1: Illustration showing the distribution of the study participants and sampling schedules for neutralising antibody measurement Note to Figure 1: *after excluding cases with a SARS-CoV-2 infection episode recorded after the booster dose.



Figure 2: Neutralizing antibodies against SARS-CoV-2 ancestral strain and VOCs (Delta, BA.1 and BA.2) in individuals with and without prior breakthrough Delta variant infection measured at different time points prior to booster vaccination and at week 2 post booster dose. Horizontal dot lines indicate assay cut-off. Numbers indicates p values.



Figure 3: Persistence of neutralising antibodies at month 3 after the booster dose in those without documented breakthrough infection after the booster dose, **A**) participants of G1, and **B**) participants of G2. Horizontal dot lines indicate assay cut-off, Numbers indicates p values.

381 Supplementary Materials For

382 Kinetics of neutralising antibodies against Omicron variant in

383 Vietnamese healthcare workers after primary immunisation with 384 ChAdOx1-S and booster with BNT162b2

- 385 Nguyen Van Vinh Chau¹, Lam Anh Nguyet², Nguyen Thanh Dung³, Nguyen Thanh
- 386 Truong⁴, Le Mau Toan³, Le Manh Hung³, Dinh Nguyen Huy Man³, Nghiem My Ngoc³,
- Huynh Phuong Thao³, Dinh Thi Bich Ty³, Pham Ba Thanh³, Nguyen Thi Han Ny², Le
- 388 Kim Thanh², Cao Thu Thuy², Nguyen To Anh², Nguyen Thi Thu Hong², Le Nguyen Truc
- 389 Nhu², Lam Minh Yen², Guy Thwaites^{2,5}, Tran Tan Thanh², and Le Van Tan², for
- 390 OUCRU COVID-19 Research Group*
- ¹Department of Health, Ho Chi Minh City, Vietnam
- ²Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
- ³Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
- ⁴Tan Phu Hospital, Ho Chi Minh City, Vietnam
- ⁵Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
- 396 University of Oxford, Oxford, UK
- 397 *Members of the groups are listed in the acknowledgments.
- 398 Correspondence: Nguyen Van Vinh Chau, chaunvv@oucru.org, and Le Van Tan,399 tanlv@oucru.org



Supplementary Figure 1: Neutralising antibodies measured at week 2 and 15 after booster vaccination in 11 HCWs with an infection episode documented after the booster dose



Supplementary Figure 2: Association between age and neutralising antibody levels to BA.1 and BA.2 measured at week 2 and 15 post booster vaccination in those without a SARS-CoV-2 infection episode recorded after the booster dose, A): 16 individuals of G1 and B) 22 individuals of G2

Note to Supplementary Figure 2: rho: Spearman's rank correction coefficient